维奥欣对抗阿霉素心脏毒性作用的初探

目的：评价阿霉素化疗合用维奥欣治疗恶性肿瘤的疗效及安全性。方法：31例恶性肿瘤患者随机被分为两组。治疗组15例于化疗前2周开始口服维奥欣，160mg，3次／d，共10周，用含阿霉素的方案作联合化疗，每4周为1个周期，共2个周期。对照组16例单用阿霉素化疗方案。结果：治疗组和对照组近期疗效总有效率分别为33．33％和37．50％（P〉0．05），差异无显著性；两组治疗后心电图异常改变分别为6．67％和43．75％（P〈0．05），心功能减低分别为0和31．25％（P〈0．05），差异均具有显著性。结论：维奥欣可以降低阿霉素治疗恶性肿瘤的心脏毒性，维持心功能，且不影响抗肿瘤效果。

Efficacy of weiaoxin against cardiac toxic action of adriamycin in treating malignancy

To evaluate the efficacy of adriamycin(ADM)and weiaoxin for malignancy.Methods:A total of 31 patients with malignancy were randomized into two groups:weiaoxin group,15 patients received treatment of weiaoxin with 160 mg,3 times/d,for 10 weeks.Control group,the other 16 patients received ADM only.Results: Overall efficiency rate was 33. 33% in weiaoxin group,and 37. 5% in control group(P>0. 05) ;the abnormity rate of electrocardiogram was 6. 67% in the weiaoxin group,and 43. 75% in the control group(P<0. 05) ;the heart func- tion reduced rate was 0 in weiaoxin group,and 31. 25% in control group(P<0. 05) .Conclusion:Efficacy of adria mycin and weiaoxin for malignancy were not effecting the afficacy of adriamycin alone in the near future,but relief the toxicity of adriamycin for heart.